RegulatoryHSCS

HeartSciences extends Front Range Ventures loan to 2027

HeartSciences Inc. has extended the maturity date of its $500,000 loan from Front Range Ventures LLC to January 29, 2027, according to an 8-K filing submitted to the U.S. Securities and Exchange Commission. The extension,…

By Gordon Ashwell·October 2, 2026·二〇二六年十〇月二日·2 min read

HeartSciences Inc. has extended the maturity date of its $500,000 loan from Front Range Ventures LLC to January 29, 2027, according to an 8-K filing submitted to the U.S. Securities and Exchange Commission. The extension, detailed in Amendment No. 8 to the Loan and Security Agreement and the No. 4 Amended and Restated Secured Promissory Note dated September 29, 2026, ties the final repayment deadline to the closing of a proposed business combination with Fortitude Mining Holdings, Inc.

The new terms set the Maturity Date as the earlier of two dates: two business days following the closing of the announced business combination with Fortitude Mining Holdings, Inc., or January 29, 2027. The company previously announced the proposed business combination on June 23, 2026. Under the amended agreement, HeartSciences is required to pay accrued unpaid interest as of September 30, 2026, on or before that date. Any accrued interest due after that date will be payable on the Maturity Date.

The loan originated on April 24, 2020, when HeartSciences borrowed $500,000 from Front Range Ventures LLC. The original secured, non-convertible promissory note accrued interest at an annual rate of 12%, compounded annually. The initial maturity date of September 30, 2021, has been extended multiple times through seven prior amendments to the loan agreement. The most recent amendment before this filing was dated September 26, 2025.

HeartSciences retains the right to repay all or part of the outstanding principal at any time before the Maturity Date. Any such voluntary repayment must be at least $50,000 and will first be applied to accrued interest before being applied to the principal amount. The company is registered on the Nasdaq Stock Market LLC under the ticker symbols HSCS for common stock and HSCSW for warrants.

The filing was signed by Andrew Simpson, who serves as President, Chief Executive Officer and Chairman of the Board of Directors for HeartSciences Inc., a Texas-based company headquartered in Southlake. The document includes exhibits for both the amended loan agreement and the restated promissory note.

Source · 來源

sec.gov

Share · 分享